Coeptis Therapeutics Holdings Inc., a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, has launched Coeptis Technologies, a new division aimed at diversifying and enhancing the company’s growth potential.
 
In line with this move, Coeptis Technologies has signed a binding Letter of Intent (LOI) with a leading company in the data security software industry with over 10,000 customers in over 100 countries. This LOI outlines the acquisition of significant technology assets, representing a key step in broadening Coeptis’ operational scope and entering the burgeoning data security market.
 
The acquisition will involve the transfer of the risk mitigation software company’s proprietary technologies, including its Data Placement Manager and Sensitive Content Manager solutions, to Coeptis’ newly established technology subsidiary. This development not only positions Coeptis as a formidable player in the data security field but also signals its dedication to innovation and long-term value creation for shareholders.
 
The current President and CEO of the risk mitigation software company will join the Coeptis management team to lead this new technology division, ensuring that Coeptis leadership remains focused on both its biotechnology assets and the expansion into technology without distraction. This strategic move underscores Coeptis’ commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors.
 
Dave Mehalick, President and CEO of Coeptis Therapeutics, commented, “We are embarking on an exciting journey of expansion that will not only enhance our presence in the biopharmaceutical sector but also venture into the high-growth technology sector. By establishing Coeptis Technologies, we are strategically positioning ourselves to leverage the unique opportunities present in these two dynamic industries. Our commitment to deliver unprecedented value to our shareholders is stronger than ever as we pursue innovative solutions that address the evolving needs of the market.”
 
This move also aligns with Coeptis’ recently announced upcoming acquisition of NexGenAI Affiliates Network.